183 related articles for article (PubMed ID: 8686779)
21. The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
Cho-Ngwa F; Liu J; Lustigman S
PLoS Negl Trop Dis; 2010 Aug; 4(8):e800. PubMed ID: 20808763
[TBL] [Abstract][Full Text] [Related]
22. Strong IgG isotypic antibody response in sowdah type onchocerciasis.
Brattig NW; Krawietz I; Abakar AZ; Erttmann KD; Kruppa TF; Massougbodji A
J Infect Dis; 1994 Oct; 170(4):955-61. PubMed ID: 7930741
[TBL] [Abstract][Full Text] [Related]
23. Immune recognition of Onchocerca volvulus proteins in the human host and animal models of onchocerciasis.
Manchang TK; Ajonina-Ekoti I; Ndjonka D; Eisenbarth A; Achukwi MD; Renz A; Brattig NW; Liebau E; Breloer M
J Helminthol; 2015 May; 89(3):375-86. PubMed ID: 24721822
[TBL] [Abstract][Full Text] [Related]
24. Associations between clinical disease, circulating antibodies and C1q-binding immune complexes in human onchocerciasis.
Sisley BM; Mackenzie CD; Steward MW; Williams JF; O'Day J; Luty AJ; Braga M; el Sheikh H
Parasite Immunol; 1987 Jul; 9(4):447-63. PubMed ID: 3498141
[TBL] [Abstract][Full Text] [Related]
25. Field evaluation of IgG4 serology for the diagnosis of onchocerciasis in children.
Ogunrinade AF; Kale OO; Chandrashekar R; Weil GJ
Trop Med Parasitol; 1992 Mar; 43(1):59-61. PubMed ID: 1598510
[TBL] [Abstract][Full Text] [Related]
26. Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients.
Tawill SA; Gallin M; Erttmann KD; Kipp W; Bamuhiiga J; Büttner DW
Trans R Soc Trop Med Hyg; 1996; 90(1):85-9. PubMed ID: 8730320
[TBL] [Abstract][Full Text] [Related]
27. Expression and characterization of Ov-47, a dominant antigen of Onchocerca volvulus.
Ghogomu SM; Souopgui J; Pelle R; Titanji VP
Exp Parasitol; 2002 Mar; 100(3):143-9. PubMed ID: 12173398
[TBL] [Abstract][Full Text] [Related]
28. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.
Mai CS; Hamm DM; Banla M; Agossou A; Schulz-Key H; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2007 Mar; 147(3):504-12. PubMed ID: 17302900
[TBL] [Abstract][Full Text] [Related]
29. Humoral responses to a secretory Onchocerca volvulus protein: differences in the pattern of antibody isotypes to recombinant Ov20/OvS1 in generalized and hyperreactive onchocerciasis.
Mpagi JL; Büttner DW; Tischendorf FW; Erttmann KD; Brattig NW
Parasite Immunol; 2000 Sep; 22(9):455-60. PubMed ID: 10972852
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal studies of skin microfilaria and antibody conversion rates in children living in an endemic focus of onchocerciasis in Nigeria.
Ogunrinade AF; Awolola SO; Rotimi O; Chandrashekar R
J Trop Pediatr; 2000 Dec; 46(6):348-51. PubMed ID: 11191146
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of onchocerciasis seroprevalence in Bioko Island (Equatorial Guinea) after years of disease control programmes.
Hernández-González A; Moya L; Perteguer MJ; Herrador Z; Nguema R; Nguema J; Aparicio P; Benito A; Gárate T
Parasit Vectors; 2016 Sep; 9(1):509. PubMed ID: 27645887
[TBL] [Abstract][Full Text] [Related]
32. Differential immune response to Onchocerca volvulus: IgG4 antibody responses differ in onchocerciasis patients from Guatemala and Ghana.
Guzmán GE; Akuffo HO; Lavebratt C; Luján R
Acta Trop; 1997 Jan; 63(1):15-31. PubMed ID: 9083582
[TBL] [Abstract][Full Text] [Related]
33. Human autoantibody to defensin: disease association with hyperreactive onchocerciasis (sowda).
Gallin MY; Jacobi AB; Büttner DW; Schönberger O; Marti T; Erttmann KD
J Exp Med; 1995 Jul; 182(1):41-7. PubMed ID: 7790822
[TBL] [Abstract][Full Text] [Related]
34. Antibody responses in onchocerciasis as a function of age and infection intensity.
Faulkner H; Gardon J; Kamgno J; Enyong P; Boussinesq M; Bradley JE
Parasite Immunol; 2001 Sep; 23(9):509-16. PubMed ID: 11589780
[TBL] [Abstract][Full Text] [Related]
35. Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda.
Kipp W; Bamhuhiiga J
Am J Trop Med Hyg; 2002 Nov; 67(5):475-9. PubMed ID: 12479547
[TBL] [Abstract][Full Text] [Related]
36. Human onchocerciasis in the lower Jos Plateau, central Nigeria: the prevalence, geographical distribution and epidemiology in Akwanga and Lafia local government areas.
Ufomadu GO; Akpa AU; Ekejindu IM
Ann Trop Med Parasitol; 1992 Dec; 86(6):637-47. PubMed ID: 1304706
[TBL] [Abstract][Full Text] [Related]
37. Unique recognition of a low molecular weight Onchocerca volvulus antigen by IgG3 antibodies in chronic hyper-reactive oncho-dermatitis (Sowda).
Cabrera Z; Buttner DW; Parkhouse RM
Clin Exp Immunol; 1988 Nov; 74(2):223-9. PubMed ID: 3224441
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Onchocerca volvulus-specific IgG4 subclass serology as an index of onchocerciasis transmission potential of three Gabonese villages.
Egwang TG; Duong TH; Nguiri C; Ngari P; Everaere S; Richard-Lenoble D; Gbakima AA; Kombila M
Clin Exp Immunol; 1994 Dec; 98(3):401-7. PubMed ID: 7994904
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of onchocercal dermatitis: possible role of parasite proteases and autoantibodies to extracellular matrix proteins.
Petralanda I; Piessens WF
Exp Parasitol; 1994 Sep; 79(2):177-86. PubMed ID: 7520005
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization and immune recognition of the extracellular superoxide dismutase from the human pathogenic parasite Onchocerca volvulus (OvEC-SOD).
Ajonina-Ekoti I; Ndjonka D; Tanyi MK; Wilbertz M; Younis AE; Boursou D; Kurosinski MA; Eberle R; Lüersen K; Perbandt M; Breloer M; Brattig NW; Liebau E
Acta Trop; 2012 Oct; 124(1):15-26. PubMed ID: 22677600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
